Gemcitabine Injection, Solution
Product Images NDC 25021-239

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gemcitabine (NDC 25021-239). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gem0a 0007 01

Chemical structure of gemcitabine showing its molecular arrangement with labeled atoms including nitrogen (N), oxygen (O), hydrogen (H), chlorine (Cl), and fluorine (F).*

FDA Label Image

Gem0a 0007 02

A Kaplan-Meier curve chart showing progression-free survival probability over months for Gemcitabine/Carboplatin versus Carboplatin alone. The chart compares progression-free survival between two groups (N=178 each), with median survival times noted as 8.6 months for Gemcitabine/Carboplatin and 5.8 months for Carboplatin. The horizontal axis represents months and the vertical axis shows progression-free probability.*

FDA Label Image

Gem0a 0007 03

A Kaplan-Meier progression-free survival curve comparing Gemcitabine/Paclitaxel combination therapy versus Paclitaxel alone. The x-axis shows time to documented disease progression in months (0 to 24), and the y-axis shows progression-free probability (0 to 1). Median progression times and statistical significance (log-rank p < 0.0001) are noted for each treatment group.*

FDA Label Image

Gem0a 0007 04

A survival probability curve comparing Gemcitabine/Cisplatin combination therapy versus Cisplatin alone over a survival time in months. The chart shows median survival and 1-year survival rates for both groups, along with statistical test values (Logrank and Wilcoxon) and p-values illustrating the difference in survival outcomes between the two treatments.*

FDA Label Image

Gem0a 0007 05

A survival time graph comparing Gemcitabine and 5-FU. The x-axis represents survival time in months, and the y-axis shows the fraction surviving. The graph features two survival curves indicating differences in survival rates over time between Gemcitabine and 5-FU.*

FDA Label Image

Gem0a 0007 06

Label for Gemcitabine Injection 200 mg per 5.26 mL (38 mg per mL) by Sagent Pharmaceuticals. The label indicates the product is for intravenous infusion only, must be diluted before use, and is a single-dose vial. It includes storage instructions and a caution that it is a cytotoxic agent. The label also provides manufacturer details and barcode information.*

FDA Label Image

Gem0a 0007 07

Label for Gemcitabine Injection, 1 gram per 26.3 mL (38 mg/mL), an intravenous solution from Sagent Pharmaceuticals. The label includes a caution for the product as a cytotoxic agent and notes it is for intravenous infusion only, with mandatory dilution before use. Storage instructions specify refrigeration between 2 and 8 degrees Celsius and to avoid freezing. The label indicates the product is sterile and nonpyrogenic.*

FDA Label Image

Gem0a 0007 08

Label for Gemcitabine Injection 2 grams per 52.6 mL (38 mg/mL) by Sagent Pharmaceuticals. The vial is for intravenous infusion only, single-dose, and must be diluted before use. The label includes cautionary statements about cytotoxicity and storage instructions, with manufacturing details from Sagent Pharmaceuticals, Schaumburg, IL, USA, and the product is made in India.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.